A Machine Learning Approach to Identify Patients With Resected Non-small-cell Lung Cancer With High Risk of Relapse

Last updated: September 18, 2023
Sponsor: University Hospital, Toulouse
Overall Status: Active - Recruiting

Phase

N/A

Condition

N/A

Treatment

Resected non small cell lung cancer

Clinical Study ID

NCT05732974
RC31/21/0519
  • Ages > 18
  • All Genders

Study Summary

Early-stage non small cell lung cancer represents 20-30% of all non small cell lung cancer and is characterized by a high survival probability after surgical resection. However, considering stage IA-IIIA non small cell lung cancer, a relapse rate of about 50% is observed, with a different survival probability on the basis of tumor node metastasis status, although patients within the same tumor node metastasis stage exhibit wide variations in recurrence rate. There are currently no validated prognostic biomarkers able to identify patients with a high risk of relapse.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patient with an early stage of non small cell lung cancer
  • Indication of surgical resection
  • Patient able to understand and give his consent
  • Patient affiliated to the health insurance

Exclusion

Exclusion Criteria:

  • Patient with another cancer in the last 5 years
  • Patient with an allergy to the contrast medium
  • Patient under legal protection

Study Design

Total Participants: 60
Treatment Group(s): 1
Primary Treatment: Resected non small cell lung cancer
Phase:
Study Start date:
March 30, 2023
Estimated Completion Date:
October 30, 2026

Study Description

This study will use data from an already available cohort of patients enrolled in the Resting study (a project funded by TRANSCAN in 2018) as a training set and data from a new concurrent cohort as validation set.

Connect with a study center

  • Julien MAZIERES

    Toulouse, 31059
    France

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.